Squawk Pod Episode Summary

Podcast: Squawk Pod (CNBC)
Episode: OpenAI’s Eye-Popping Raise & Hair Today, Hair Forever
Date: April 1, 2026

Episode Theme & Overview

This episode covers two major stories:

1. OpenAI’s Record Funding Round and Implications for Investors – with an in-depth conversation featuring Ark Invest CEO Cathie Wood about OpenAI’s astounding $850+ billion valuation and the democratization of access to private tech investments.
2. The Hair Loss Revolution – an exploration of Veradermyx, the biotech startup aiming to disrupt the $10B+ hair loss market, with insights from CEO Dr. Reed Waldman.

Supporting segments include market updates, SpaceX IPO news, and high-level international coverage on the Strait of Hormuz conflict and its market impacts.

Opening Market & News Rundown

Recent Market Performance & War Impact ([02:26–06:46])

• Hosts: Becky Quick, Joe Kernan
• Key Points:
  • Major indices had their best day since May, but suffered losses for the month/quarter (S&P 500 down 4.6% for Q1, Nasdaq down >7%).
  • Nasdaq still in correction territory.
  • Market rally driven by hope for de-escalation in the Middle East war.
  • Oil prices down sharply: WTI at $100, Brent Crude at $103.
  • Nike faces sales declines, especially in China, and ongoing controversies and supply chain issues.

Memorable Quote:
Becky Quick: “It all adds up to a lot. They thought they’d be in a better place than they are right now after the change.” (06:18)

Strait of Hormuz & Middle East Tensions ([06:55–14:05])

• Correspondent: Dan Murphy (Dubai)
• Key Points:
  • President Trump signals possible US withdrawal from Iran in 2–3 weeks; will address the nation tonight.
  • UAE preparing to join coalition to forcefully reopen the Strait of Hormuz.
  • Gulf states worried about US pullout; debate over region’s stability post-conflict.
  • Recent Iranian missile launches and ongoing attacks; ambiguity about regime change and future threats.
  • Markets rallied on hints of de-escalation but uncertainties remain.

Notable Quotes:
Dan Murphy: “It’s pretty clear now that not all of Washington’s Gulf allies want the war to end just yet.” (10:04)
Joe Kernan: “Iran is a huge country... I just wonder what’s being presented to the President in terms of special forces. He mentioned something called the discombobulator...” (11:26)

SpaceX IPO Update ([14:14–15:21])

• Hosts: Joe Kernan, Becky Quick
• Key Points:
  • SpaceX IPO could debut as early as June; project codename: Project Apex.
  • Over 20 banks involved, including Morgan Stanley, Goldman Sachs, and more.
  • Elon Musk promises larger retail investor allocations vs. traditional IPOs.

OpenAI’s Eye-Popping Raise ([15:24–29:27])

Introduction ([15:24–17:15])

• OpenAI closed a $122B round—now valued at $852B.
• Investors: Amazon, Nvidia, SoftBank—each investing tens of billions.
• OpenAI shares to be included in several Ark Invest ETFs.
• Growing anticipation for OpenAI IPO.

Cathie Wood Interview ([19:11–29:27])

• Guest: Cathie Wood, CEO/CIO of Ark Invest

• Key Segments & Quotes:

  OpenAI Investment & Democratization ([20:09–22:16])

  • Wood: “We’re continuing to serve as a bridge from the private markets into the public markets... focus exclusively on technologically enabled innovation.” (20:09)
  • ARK Venture Fund was the first to hold OpenAI; it’s now #2 in the portfolio.
  • Now added to ARKK, ARKW, ARKF ETFs – allowing retail investors partial access to private AI giants.

  Why OpenAI? ([21:16–22:16])

  • Wood: “OpenAI wanted to partner with us... to help this democratization movement.” (21:27)
  • Emphasis on allowing non-accredited investors access to high-growth opportunities.

  The AI Tipping Point ([22:16–23:39])

  • Wood: “AI is the biggest catalyst for innovation in industry.” (21:04)
  • Job market: AI as a net job creator, but warns about declining entry-level roles.
  • Advice to youth: “Go start a business with ChatGPT... experiment, just go for it.” (22:34)

  The Rise of AI Agents ([23:39–24:29])

  • Wood: “I see our chief futurist... has four or five agents working for him... it's astonishing… we need $2,000/month worth of tokens so that we can send these agents out.” (23:46)

  Investing & AI in Asset Management ([24:48–26:05])

  • Asset management shifting to passive, benchmark-driven strategies. AI will be very effective at these, but disruptive research still requires human insight for now.

  Ark Performance & Tech Convergence ([26:05–27:24])

  • Wood expects Ark to outperform as tech convergence (AI, robotics, energy storage, blockchain, genomics) accelerates.
  • “I think we’re coming out of that drought and this technology revolution, many more people are beginning to understand because they’re using AI...” (26:13)

  Crypto Outlook ([27:24–29:18])

  • Wood: “Bitcoin... has been in a bit of a winter... I think we're in a bottoming out phase now.” (27:38)
  • Institutional adoption seen as reducing volatility. Anticipates less severe drawdowns in future cycles.

  Memorable Closing
  Joe Kernan: “Could be something really risky, like Nike stock at 180, now it’s 40.” (29:18)

The Hair Loss Revolution: Veradermyx Interview ([31:24–38:43])

Background & Setup

• Hosts: Joe Kernan, Becky Quick
• Guest: Dr. Reed Waldman, CEO, Veradermyx

The Science & Opportunity ([32:52–34:21])

• Pattern hair loss affects 80 million Americans (10x more than psoriasis).
• No FDA-approved hair loss drug in almost 30 years.
• Veradermyx’s drug: same active molecule as Rogaine (minoxidil), but reengineered as a consistent, steady oral treatment to maximize efficacy and minimize side effects.

Dr. Waldman: “We give consistent and durable exposures at the follicle throughout the day... to try and reduce side effects.” (33:24)

Clinical Data & Impact ([33:51–34:21])

• Phase II showed fast, consistent, quantifiable hair growth in most trial participants.
• Three Phase III trials underway—including first oral trial for female pattern hair loss.

Dr. Waldman: “People get visible results as early as two months... consistent, intense... out of proportion to what’s been seen previously.” (33:56)

Safety, Side Effects & Differentiation ([35:09–36:21])

• Major side effect concern with current treatments (Propecia/finasteride) is sexual dysfunction and hormonal effects.
• Veradermyx’s drug not expected to cause hormonal side effects.
• Question addressed: excessive hair growth elsewhere not seen as a major issue so far.

Dr. Waldman: “Here we have a non-hormonal medication. It's not anticipated to cause things like erectile dysfunction...” (35:45)

Competitive Landscape & Future ([36:24–37:25])

• Only oral treatment in US clinical trials.
• Patient preference for oral over topical treatments.
• Propecia (finasteride) effective only in men; new drug could be a breakthrough for women.

Mechanism, Dosing & Safety ([37:38–38:09])

• Old minoxidil: blood pressure drug, short-acting, spikes drive side effects.
• New drug: steady, low dose to avoid cardiovascular or unwanted hair side effects.

Humor & Personal Touch

• Hosts recall Joe’s infamous "toupee challenge" with Becky and the leaf blower proving his hair is real, riffing on TV skepticism and personal experiences with hair loss.
• Light banter about side effects and industry quirks.

Notable Quotes

• Cathie Wood:

  • “We’re continuing to serve as a bridge from the private markets into the public markets... focus exclusively on technologically enabled innovation.” ([20:09])
  • “AI is the biggest catalyst for innovation in industry.” ([21:04])
  • “Go start a business with ChatGPT... experiment, just go for it.” ([22:34])

• Dr. Reed Waldman:

  • “We give consistent and durable exposures at the follicle throughout the day... to try and reduce side effects.” ([33:24])
  • “We do not anticipate [excessive body hair] to be a meaningful tolerability challenge.” ([36:00])

• Joe Kernan:

  • “Could be something really risky, like Nike stock at 180, now it’s 40.” ([29:18])
  • “I always say: it’s real human—no, it’s my real human hair!” ([34:21])

Timestamps: Key Segments

• [02:26] – Market update & war impacts
• [06:55] – Nike troubles in China & broader industry context
• [07:23] – Middle East/Strait of Hormuz update with Dan Murphy
• [14:14] – SpaceX mega-IPO details
• [15:24] – OpenAI’s record funding details; Ark Invest’s pivot
• [19:11] – Cathie Wood interview: OpenAI access, ETF inclusion, AI revolution, investing for the future
• [31:24] – Introduction to the toupee challenge & hair loss segment
• [32:52] – Dr. Reed Waldman on Veradermyx science, efficacy, clinical timeline
• [36:46] – Veradermyx’s unique competitive position, oral minoxidil explained
• [38:43] – Humorous closing remarks and segment wrap

Tone & Style

• Conversational, insightful, sometimes irreverent: the hosts mix data-heavy discussion with banter and inside jokes, especially around personal experiences (hair loss/toupee jokes).
• Accessible but not dumbed-down: guests (Wood, Waldman) provide both high-level perspectives and technical details.
• Forward-looking, tech-centric: strong focus on democratizing finance, AI revolution, and biotech disruption.

In Summary

This Squawk Pod episode covers seismic shifts in tech and biotech investment:

• OpenAI’s massive funding and increased mainstream investor access via Ark ETFs signals a new era in AI investment and the push to democratize private market opportunities.
• Cathie Wood stakes her case as a radical optimist on AI, tech convergence, and innovation investing.
• The hair loss segment offers both comic relief and genuine insight into a potentially transformative drug (Veradermyx), reflecting the show's blend of business seriousness and playful authenticity.
• Market news, global conflicts, and IPO updates round out a content-rich, engaging episode.

Ideal for: Investors, tech/AI enthusiasts, biotech followers, and anyone who enjoys the intersection of market analysis and real-world innovation.